Abstract
Tardive dyskinesia (TD) is a severe adverse effect of chronic antipsychotic drug treatment. In addition to clinical risk factors, TD susceptibility is influenced by genetic predisposition. Recently, Syu et al. (2010) reported a genome-wide association screening of TD in Japanese schizophrenia patients. The best result was association of single-nucleotide polymorphism (SNP) rs2445142 in the HSPG2 (heparan sulfate proteoglycan 2) gene with TD. In the present study, we report a replication study of the five top Japanese TD-associated SNPs in two Caucasian TD samples. Applying logistic regression and controlling for relevant clinical risk factors, we were able to replicate the association of HSPG2 SNP rs2445142 with TD in a prospective study sample of 179 Americans of European origin by performing a secondary analysis of the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) genome-wide association study data set, and using a perfect proxy surrogate marker (rs878949; P=0.039). An association of the ‘G’ risk allele of HSPG2 SNP rs2445142 with TD was also shown in a sample of Jewish Israeli schizophrenia patients (retrospective, cross-sectional design; P=0.03). Although the associations were only nominally significant, the findings provide further support for the possible involvement of HSPG2 in susceptibility to TD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Blanchet PJ . Antipsychotic drug-induced movement disorders. Can J Neurol Sci 2003; 30: S101–S107.
Haddad PM, Dursun SM . Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmacol 2008; 23 (Suppl): 15–26.
Glazer WM, Morgenstern H, Doucette JT . Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133–139.
de Leon J . The effect of atypical versus typical antipsychotics on tardive dyskinesia: a Naturalistic Study. Eur Arch Psychiatry Clin Neurosci 2007; 257: 169–172.
Remington G . Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007; 20: 131–137.
Correll CU, Schenk EM . Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008; 21: 151–156.
Yassa R, Jeste DV . Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bull 1992; 18: 701–715.
Kane JM . Tardive dyskinesia: epidemiological and clinical presentation. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology: The 4th Generation of Progress. Raven Press: New York, 1995.
Tenback DE, van Harten PN, van Os J . Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009; 24: 2309–2315.
Lerer B, Segman RH . Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin Neurosci 2006; 8: 85–94.
Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375–379.
Ismail B, Cantor-Graae E, McNeil TF . Neurodevelopmental origins of tardive like dyskinesia in schizophrenia patients and their siblings. Schizophr Bull 2001; 27: 629–641.
Egan MF, Apud J, Wyatt RJ . Treatment of tardive dyskinesia. Schizophr Bull 1997; 23: 583–609.
Sagara Y . Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 71: 1002–1012.
Naidu PS, Singh A, Kulkarni SK . Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 2002; 136: 193–200.
Delfs JM, Ellison GD, Mercugliano M, Chesselet MF . Expression of glutamic acid decarboxylase mRNA in striatum and pallidum in an animal model of tardive dyskinesia. Exp Neurol 1995; 133: 175–188.
Sakai K, Gao XM, Hashimoto T, Tamminga CA . Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse 2001; 39: 152–160.
Fenton WS . Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000; 61 (Suppl 4): 10–14.
Pappa S, Dazzan P . Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009; 39: 1065–1076.
Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN . Dyskinesia and parkinsonism in antipsychotic-naive patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull 2010; 36: 723–731.
Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105–119.
Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN et al. Combined analysis of 635 patients confirms an age-related association of the serotonin receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8: 411–425.
Bakker PR, van Harten PN, van Os J . Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83: 185–192.
Bakker PR, van Harten PN, van Os J . Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544–556.
Patsopoulos NA, Ntzani EE, Zintzaras E, Ioannidis JP . CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005; 15: 151–158.
Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL, Thelma BK . Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J 2007; 7: 305–311.
Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 2010; 153B: 336–340.
Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller del D et al. Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67: 279–282.
Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B . Evidence for association of the GLI2 gene with tardive dyskinesia in chronic schizophrenia patients. Mov Disord 2010; 25: 2809–2817.
Syu A, Ishiguro H, Inada T, Horiuchi Y, Tanaka S, Ishikawa M . Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010; 35: 1155–1164.
Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18: 317–323.
Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247–253.
Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6: 225–229.
Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, Revised edn. Department of Health, Education and Welfare: Washington DC.
Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486–487.
Steen VM, Llie R, McEwan T, McCreadie RG . Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139–145.
Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM . Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131: 174–179.
Løvlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM . Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. Int J Neuropsychopharmacol 2000; 3: 61–65.
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–1223.
Sullivan PF, Lin D, Tzeng JY, van den Oord E, Perkins D, Stroup TS et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 2008; 13: 570–584.
Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15–31.
Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D . Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904–909.
Reich D, Price AL, Patterson N . Principal component analysis of genetic data. Nat Genet 2008; 40: 646–649.
Nasrallah HA . Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry 2006; 18: 57–62.
Pierre JM . Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 2005; 28: 191–208.
Chong SA, Mahendran R, Machin D, Chua HC, Parker G, Kane J . Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharmacol 2002; 22: 26–30.
Bhatia T, Sabeeha MR, Shriharsh V, Garg K, Segman RH, Uriel HL et al. Clinical and familial correlates of tardive dyskinesia in India and Israel. J Postgrad Med 2004; 50: 167–172.
Lin PI, Vance JM, Pericak-Vance MA, Martin ER . No gene is an island: the flip-flop phenomenon. Am J Hum Genet 2007; 80: 531–538.
Zaykin V, Shibata K . Genetic flip-flop without an accompanying change in linkage disequilibrium. Am J Hum Genet 2008; 82: 794–796.
Crowley JJ, Sullivan PF, McLeod HL . Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics 2009; 10: 161–163.
Turner ST, Bailey KR, Fridley BL, Chapman AB, Schwartz GL, Chai HS et al. Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic. Hypertension 2008; 52: 359–365.
Sullivan PF . Spurious genetic associations. Biol Psychiatry 2007; 61: 1121–1126.
van den Oord EJ, Kuo PH, Hartmann AM, Webb BT, Möller HJ, Hettema JM et al. Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry 2008; 65: 1062–1071.
Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani A et al. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron 1994; 12: 219–234.
Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A et al. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2004; 128B: 123–125.
Ruigrok YM, Rinkel GJ, Wijmenga C, Kasuya H, Tajima A, Takahashi T et al. Association analysis of genes involved in the maintenance of the integrity of the extracellular matrix with intracranial aneurysms in a Japanese cohort. Cerebrovasc Dis 2009; 28: 131–134.
Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K . Cholinergic medication for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2002; 3: CD000207.
Rotundo RL, Rossi SG, Kimbell LM, Ruiz C, Marrero E . Targeting acetylcholinesterase to the neuromuscular synapse. Chem Biol Interact 2005; 157–158: 15–21.
Acknowledgements
This study was supported in part by a grant from the Michael J Fox Foundation (to BL). The principal investigators of the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) trial were Jeffrey A Lieberman, T Scott Stroup, and Joseph P McEvoy. The CATIE trial was funded by a grant from the National Institute of Mental Health (N01 MH900001) along with MH074027 (PI PF Sullivan). Genotyping was funded by Eli Lilly and Company.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Greenbaum, L., Alkelai, A., Zozulinsky, P. et al. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 12, 513–520 (2012). https://doi.org/10.1038/tpj.2011.32
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2011.32
Keywords
This article is cited by
-
Genome wide study of tardive dyskinesia in schizophrenia
Translational Psychiatry (2021)
-
Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes
The Pharmacogenomics Journal (2016)
-
Do Tardive Dyskinesia and l-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study
Journal of Molecular Neuroscience (2013)